Shanghai, China · Founded 2018 · Privately Held (backing)
Developer of personalized dendritic cell tumor vaccines intended to provide new treatment approaches and strategies for relapsed and refractory tumors. Hengsai Bio is based in Shanghai, China and was founded in 2018. It has raised $18.6 million.
Last price · $/share
—
Implied valuation
—
Total raised
$18.6M
Last round
—
Team — not yet on record
No current team members for Hengsai Bio are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Hengsai Bio with a free account
·Watch Hengsai Bio: the Monday email on marks, rounds and moves
